$ORIC News

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcript

Oric Pharmaceuticals’ Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial

ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026

ORIC Plans Global Phase 3 Redwood-1 Trial Of Enozertinib In 1L EGFR Atypical NSCLC In 1H 2027 After Phase 1b Showing 84% Confirmed Systemic ORR, 70% Confirmed Intracranial ORR

ORIC Stock In Focus As New Lung Cancer Trial Data Heads To ESMO 2026

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26

Does ORIC (ORIC) Using Off‑Balance‑Sheet Funding for ORIC‑259 Redefine Its R&D Risk Strategy?

ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development

ORIC Pharmaceuticals Announces Agreement With Cancer Research UK To Advance Potential CIP2A-Targeted Therapy Into Clinical Development

Leerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26

ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27

Is ORIC Pharmaceuticals' (ORIC) Equity-Funded ESOP Masking or Clarifying Its Widening Net Losses?